查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1211005

難治性抑鬱症 (TRD) 治療的全球市場規模和預測：按藥物類型、分銷渠道和地區分析，2022-2029 年

Global Treatment-resistant Depression Treatment Market Size study & Forecast, by Drug Type, by Distribution Channel and Regional Analysis, 2022-2029
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3個工作天內

價格

2021 年全球難治性抑鬱症治療市場價值約 15.2 億美元，預計在 2022-2029 年預測期內將以超過 9.0% 的健康增長率增長。

難治性抑鬱症 (TRD) 是重度抑鬱症 (MDD) 的一種形式，是由於在治療過程中對至少兩種抗抑鬱藥的反應不當所致。 炎症系統的激活、神經遞質功能障礙、異常的神經元活動、憂鬱的臨床特徵、雙極性和較高的創傷負荷是與這種疾病相關的一些病症。 與口服給藥相比，對其他給藥途徑的偏好增加、藥物開發項目數量增加以及醫療成本上升是推動全球市場需求的主要因素。

這種情緒障礙的患病率上升是促進市場增長的關鍵因素。 當兩種抗抑鬱藥服用足夠長的時間（通常為 6 週）並且沒有反應時，就會發生 TRD。 這種疾病患病率的增加導致對難治性抑鬱症的治療需求增加。 Springer 報告說，到 2021 年 8 月，全球將有超過 3 億人患有重度抑鬱症，其中超過三分之一的人患有難治性抑鬱症。我知道這一點。 因此，不斷增加的疾病負擔是市場增長的催化劑。 此外，在預測期內，市場主要參與者對研發活動的投資增加和舉措不斷增加，帶來了各種有利可圖的機會。 然而，有限的治療途徑以及對這種情緒障礙患者的診斷和管理指南缺乏明確性限制了整個 2022-2029 年預測期內的市場增長。

全球難治性抑鬱症治療市場研究考慮的主要區域是亞太地區、北美、歐洲、拉丁美洲和世界其他地區。 由於指南的增加、藥物批准、研發的大量投資以及市場參與者的關注度增加，北美在收入方面佔據了市場主導地位。 另一方面，由於患有難治性抑鬱症的患者數量增加以及市場空間中對情緒障礙治療相關意識的提高等因素，預計亞太地區在預測期內將以最高複合年增長率增長。增加。

這項研究的目的是定義近年來各個細分市場和國家的市場規模，並預測未來幾年的價值。 該報告旨在捕捉被調查國家工業的定性和定量方面。

它還提供了關鍵方面的詳細信息，例如決定市場未來增長的驅動因素和挑戰。 此外，它還包含供利益相關者投資的微觀市場潛在機會，以及對主要參與者的競爭格局和產品供應的深入分析。

內容

第 1 章執行摘要

  • 市場概況
  • 2019-2029 年各細分市場的全球市場估計和預測
    • 難治性抑鬱症治療市場：按地區劃分，2019-2029 年
    • 難治性抑鬱症治療市場：按藥物類型分類，2019-2029 年
    • 抗抑鬱藥物市場：按分銷渠道，2019-2029 年
  • 主要趨勢
  • 調查方法
  • 調查先決條件

第 2 章難治性抑鬱症的全球市場定義和範圍

  • 調查的目的
  • 市場定義和範圍
    • 調查範圍
    • 工業發展
  • 調查年份
  • 貨幣兌換率

第 3 章難治性抑鬱症的全球市場動態

  • 抗抑鬱藥市場影響分析 (2019-2029)
    • 市場驅動因素
      • 難治性抑鬱症患病率上升
      • 增加藥物開發項目
    • 市場挑戰
      • 有限的治療選擇
      • 缺乏針對這種情緒障礙患者的明確診斷和管理指南
    • 市場機會
      • 增加對研發活動的投資
      • 主要市場進入者的舉措增加

第 4 章全球難治性抑鬱症治療市場行業分析

  • 波特 5 力模型
    • 供應商的議價能力
    • 買家的議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭公司之間的敵對關係
  • 波特 5 力模型的未來方法 (2019-2029)
  • 害蟲分析
    • 政治
    • 經濟的
    • 社交
    • 技術
  • 頂級投資機會
  • 關鍵成功策略
  • 行業專家的展望
  • 分析師的結論和建議

第 5 章風險評估：COVID-19 的影響

  • 評估 COVID-19 對行業的總體影響
  • COVID-19 之前和 COVID-19 之後的市場情景

第 6 章治療難治性抑鬱症的全球市場，按藥物類型分列

  • 市場概況
  • 難治性抑鬱症治療的全球市場：按藥物類型進行的性能潛力分析
  • 2019-2029 年按藥物類型劃分的難治性抑鬱症治療全球市場估計和預測
  • 抗抑鬱藥市場細分分析
    • 國家導彈防禦局
    • 抗抑鬱藥
    • 抗精神病藥
    • 其他

第 7 章：治療難治性抑鬱症的全球市場：按分銷渠道

  • 市場概況
  • 治療難治性抑鬱症藥物的全球市場：按分銷渠道進行的性能潛力分析
  • 2019-2029 年全球難治性抑鬱症治療市場、按分銷渠道估算和預測
  • 抗抑鬱藥市場細分分析
    • 醫院藥房
    • 藥店和零售藥店
    • 在線藥店

第 8 章抗抑鬱藥物的全球市場：區域分析

  • 抗抑鬱藥市場，按地區劃分的市場概況
  • 北美
    • 美國
      • 2019-2029 年按藥物類型估算和預測
      • 2019-2029 年各分銷渠道的估計和預測
    • 加拿大
  • 歐洲難治性抑鬱症藥物市場概況
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 意大利
    • 其他歐洲地區
  • 亞太地區難治性抑鬱症治療市場概況
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 韓國
    • 其他亞太地區
  • 拉丁美洲難治性抑鬱症治療市場概況
    • 巴西
    • 墨西哥
    • 其他拉丁美洲地區
  • 世界其他地區

第 9 章衝突信息

  • 頂級市場策略
  • 公司簡介
    • 禮來公司
      • 主要信息
      • 概覽
      • 財務信息（取決於數據可用性）
      • 產品概述
      • 近期趨勢
    • GlaxoSmithKline Plc
    • Pfizer Inc.
    • Janssen Global Services, LLC（Johnson & Johnson Services, Inc.）
    • AbbVie Inc.
    • AstraZeneca Plc
    • H. Lundbeck A/S
    • Sandoz International GmbH（Novartis AG）
    • Par Pharmaceutical（Endo International plc）
    • Otsuka Pharmaceutical Co., Ltd.（Otsuka Holdings Co., Ltd.）

第 10 章研究過程

  • 研究過程
    • 數據挖掘
    • 分析
    • 市場評估
    • 驗證
    • 出版
  • 調查屬性
  • 調查先決條件

Global Treatment-resistant Depression Treatment Market is valued at approximately USD 1.52 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 9.0% over the forecast period 2022-2029. Treatment-Resistant Depression (TRD) is a variety of Major Depressive Disorder (MDD) that cause due to the improper response of at least two antidepressants in the treatment process. The inflammatory system activation, neurotransmitter dysfunction, abnormal neural activity, melancholic clinical features, bipolarity, and a higher traumatic load are some conditions that are associated with this disorder. The rising inclination towards other routes of administration compared to oral administration, the increasing drug development projects, and increasing healthcare expenditure are some primary factors that are propelling the market demand across the globe.

The rise in the prevalence of this mood disorder is a key factor that is contributing to the market's growth. TRD occurs when a person hasn't reacted to two separate antidepressant doses taken for a sufficient amount of time, typically six weeks. The demand for the treatment of treatment-resistant depression has increased as a result of the rise in the prevalence of this medical disease. Springer reported that in August 2021, there are more than 300 million individuals worldwide suffer from significant depressive disorders, and over one-third of those people have depression that is treatment-resistant depression. Hence, the rising disease burden is a catalyzing factor for the market's growth. Moreover, rising investment in research and development activities, as well as the increasing initiatives by the key market players are presenting various lucrative opportunities over the forecasting years. However, the limited therapeutic measure and lack of clarity in guidelines for diagnosis and management of this mood disorder patients are restricting the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Treatment-resistant Depression Treatment Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the increasing number of guidelines and approval of drugs, along with the significant R&D investment and increasing focus of market players. Whereas, the Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the growing patient population suffering from treatment-resistant depressive disorder, as well as increasing awareness related to the treatment of mood disorder in the market space.

Major market players included in this report are:

Eli Lilly and Company

GlaxoSmithKline Plc

Pfizer Inc.

Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)

AbbVie Inc.

AstraZeneca Plc

H. Lundbeck A/S

Sandoz International GmbH (Novartis AG)

Par Pharmaceutical (Endo International plc)

Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings Co., Ltd.)

Recent Developments in the Market:

  • In August 2022, Merck Sharp & Dohme LLC initiated the clinical trial of its Phase IIa to evaluate the efficacy and safety of the company's MK-1942 among treatment-resistant depression patients.
  • In July 2022, Novartis Pharmaceuticals declared that the company is planning to initiate a Phase 2 clinical trial of MIJ821 (ketamine) for treatment-resistant depressive disorders in September 2022.

Global Treatment-resistant Depression Treatment Market Report Scope:

Historical Data: 2019-2020-2021

Base Year for Estimation: 2021

Forecast period: 2022-2029

Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

Segments Covered: Drug Type, Distribution Channel, Region

Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World

Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Type:

NMDA

Antidepressants

Antipsychotics

Others

By Distribution Channel:

Hospital Pharmacies

Drug Stores & Retail Pharmacies

Online Pharmacies

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

RoLA

Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Treatment-resistant Depression Treatment Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Treatment-resistant Depression Treatment Market, by Drug Type, 2019-2029 (USD Billion)
    • 1.2.3. Treatment-resistant Depression Treatment Market, by Distribution Channel, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Treatment-resistant Depression Treatment Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Treatment-resistant Depression Treatment Market Dynamics

  • 3.1. Treatment-resistant Depression Treatment Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rise in the prevalence of treatment-resistant depression
      • 3.1.1.2. Increasing drug development projects
    • 3.1.2. Market Challenges
      • 3.1.2.1. Limited therapeutic measure
      • 3.1.2.2. Lack of clarity in guidelines for diagnosis and management of this mood disorder patients
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Rising investment in research and development activities
      • 3.1.3.2. Increasing initiatives by the key market players

Chapter 4. Global Treatment-resistant Depression Treatment Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Treatment-resistant Depression Treatment Market, by Drug Type

  • 6.1. Market Snapshot
  • 6.2. Global Treatment-resistant Depression Treatment Market by Drug Type, Performance - Potential Analysis
  • 6.3. Global Treatment-resistant Depression Treatment Market Estimates & Forecasts by Drug Type 2019-2029 (USD Billion)
  • 6.4. Treatment-resistant Depression Treatment Market, Sub Segment Analysis
    • 6.4.1. NMDA
    • 6.4.2. Antidepressants
    • 6.4.3. Antipsychotics
    • 6.4.4. Others

Chapter 7. Global Treatment-resistant Depression Treatment Market, by Distribution Channel

  • 7.1. Market Snapshot
  • 7.2. Global Treatment-resistant Depression Treatment Market by Distribution Channel, Performance - Potential Analysis
  • 7.3. Global Treatment-resistant Depression Treatment Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
  • 7.4. Treatment-resistant Depression Treatment Market, Sub Segment Analysis
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Drug Stores & Retail Pharmacies
    • 7.4.3. Online Pharmacies

Chapter 8. Global Treatment-resistant Depression Treatment Market, Regional Analysis

  • 8.1. Treatment-resistant Depression Treatment Market, Regional Market Snapshot
  • 8.2. North America Treatment-resistant Depression Treatment Market
    • 8.2.1. U.S. Treatment-resistant Depression Treatment Market
      • 8.2.1.1. Drug Type breakdown estimates & forecasts, 2019-2029
      • 8.2.1.2. Distribution Channel breakdown estimates & forecasts, 2019-2029
    • 8.2.2. Canada Treatment-resistant Depression Treatment Market
  • 8.3. Europe Treatment-resistant Depression Treatment Market Snapshot
    • 8.3.1. U.K. Treatment-resistant Depression Treatment Market
    • 8.3.2. Germany Treatment-resistant Depression Treatment Market
    • 8.3.3. France Treatment-resistant Depression Treatment Market
    • 8.3.4. Spain Treatment-resistant Depression Treatment Market
    • 8.3.5. Italy Treatment-resistant Depression Treatment Market
    • 8.3.6. Rest of Europe Treatment-resistant Depression Treatment Market
  • 8.4. Asia-Pacific Treatment-resistant Depression Treatment Market Snapshot
    • 8.4.1. China Treatment-resistant Depression Treatment Market
    • 8.4.2. India Treatment-resistant Depression Treatment Market
    • 8.4.3. Japan Treatment-resistant Depression Treatment Market
    • 8.4.4. Australia Treatment-resistant Depression Treatment Market
    • 8.4.5. South Korea Treatment-resistant Depression Treatment Market
    • 8.4.6. Rest of Asia Pacific Treatment-resistant Depression Treatment Market
  • 8.5. Latin America Treatment-resistant Depression Treatment Market Snapshot
    • 8.5.1. Brazil Treatment-resistant Depression Treatment Market
    • 8.5.2. Mexico Treatment-resistant Depression Treatment Market
    • 8.5.3. Rest of Latin America Treatment-resistant Depression Treatment Market
  • 8.6. Rest of The World Treatment-resistant Depression Treatment Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. Eli Lilly and Company
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Product Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. GlaxoSmithKline Plc
    • 9.2.3. Pfizer Inc.
    • 9.2.4. Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)
    • 9.2.5. AbbVie Inc.
    • 9.2.6. AstraZeneca Plc
    • 9.2.7. H. Lundbeck A/S
    • 9.2.8. Sandoz International GmbH (Novartis AG)
    • 9.2.9. Par Pharmaceutical (Endo International plc)
    • 9.2.10. Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings Co., Ltd.)

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Treatment-resistant Depression Treatment Market, report scope
  • TABLE 2. Global Treatment-resistant Depression Treatment Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Treatment-resistant Depression Treatment Market estimates & forecasts by Drug Type 2019-2029 (USD Billion)
  • TABLE 4. Global Treatment-resistant Depression Treatment Market estimates & forecasts by Distribution Channel 2019-2029 (USD Billion)
  • TABLE 5. Global Treatment-resistant Depression Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 6. Global Treatment-resistant Depression Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Treatment-resistant Depression Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Treatment-resistant Depression Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Treatment-resistant Depression Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Treatment-resistant Depression Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Treatment-resistant Depression Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Treatment-resistant Depression Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Treatment-resistant Depression Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. Global Treatment-resistant Depression Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. U.S. Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 16. U.S. Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 17. U.S. Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 18. Canada Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 19. Canada Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 20. Canada Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 21. UK Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 22. UK Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 23. UK Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 24. Germany Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 25. Germany Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 26. Germany Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 27. France Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 28. France Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 29. France Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 30. Italy Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 31. Italy Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 32. Italy Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 33. Spain Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 34. Spain Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 35. Spain Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 36. RoE Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 37. RoE Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 38. RoE Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 39. China Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 40. China Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 41. China Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 42. India Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 43. India Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 44. India Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 45. Japan Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 46. Japan Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 47. Japan Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 48. South Korea Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 49. South Korea Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 50. South Korea Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 51. Australia Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 52. Australia Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 53. Australia Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 54. RoAPAC Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 56. RoAPAC Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 57. Brazil Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 58. Brazil Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 59. Brazil Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 60. Mexico Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 61. Mexico Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 62. Mexico Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 63. RoLA Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 64. RoLA Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 65. RoLA Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 66. Row Treatment-resistant Depression Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 67. Row Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 68. Row Treatment-resistant Depression Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 69. List of secondary sources, used in the study of global Treatment-resistant Depression Treatment Market
  • TABLE 70. List of primary sources, used in the study of global Treatment-resistant Depression Treatment Market
  • TABLE 71. Years considered for the study
  • TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Treatment-resistant Depression Treatment Market, research methodology
  • FIG 2. Global Treatment-resistant Depression Treatment Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Treatment-resistant Depression Treatment Market, key trends 2021
  • FIG 5. Global Treatment-resistant Depression Treatment Market, growth prospects 2022-2029
  • FIG 6. Global Treatment-resistant Depression Treatment Market, porters 5 force model
  • FIG 7. Global Treatment-resistant Depression Treatment Market, pest analysis
  • FIG 8. Global Treatment-resistant Depression Treatment Market, value chain analysis
  • FIG 9. Global Treatment-resistant Depression Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Treatment-resistant Depression Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Treatment-resistant Depression Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Treatment-resistant Depression Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Treatment-resistant Depression Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Treatment-resistant Depression Treatment Market, regional snapshot 2019 & 2029
  • FIG 15. North America Treatment-resistant Depression Treatment Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Treatment-resistant Depression Treatment Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia pacific Treatment-resistant Depression Treatment Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Treatment-resistant Depression Treatment Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Treatment-resistant Depression Treatment Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable